California chronic pain biotech co‑founded by Vivek Ramaswamy to go public via reverse merger

A California biotech company that has developed a chronic pain medication already approved for use in Italy is preparing to list on a U.S. exchange.

The firm, co‑founded by entrepreneur Vivek Ramaswamy, plans to achieve a public listing through a reverse merger, a method that allows private companies to become listed without a traditional IPO.

The move reflects a growing preference among smaller biotech firms for reverse mergers as a faster, less costly path to public markets, even as the drug remains unapproved in the United States.